O3-14-01: NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIP-1, NEUROGRANIN, SNAP-25 AND YKL-40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN)

2006 ◽  
Vol 14 (7S_Part_19) ◽  
pp. P1059-P1059
Author(s):  
Anne M. Fagan ◽  
Yan Li ◽  
Kaitlin Todd ◽  
Elizabeth M. Herries ◽  
Rachel L. Henson ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Autosomal Dominant ◽  
Neuronal Injury ◽  
Synaptic Dysfunction ◽  
Csf Biomarkers

CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease

2020 ◽  
Author(s):  
Anne M. Fagan ◽  
Rachel L. Henson ◽  
Yan Li ◽  
Anna H. Boerwinkle ◽  
Chengjie Xiong ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Alzheimer Disease ◽  
Autosomal Dominant ◽  
Csf Biomarkers

scholarly journals Cross‐modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease

2020 ◽  
Vol 16 (S4) ◽  
Author(s):  
Lisa Vermunt ◽  
Courtney L. Sutphen ◽  
Ellen Dicks ◽  
Carlos Cruchaga ◽  
Michael Ewers ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Grey Matter ◽  
Autosomal Dominant ◽  
Csf Biomarkers ◽  
Network Disruption

scholarly journals IC-P-117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study

2016 ◽  
Vol 12 ◽  
pp. P87-P88
Author(s):  
Nelly Joseph-Mathurin ◽  
Andrei G. Vlassenko ◽  
Anne M. Fagan ◽  
Yi Su ◽  
Karl A. Friedrichsen ◽  
...  
Keyword(s):  
Autosomal Dominant ◽  
Neuronal Injury ◽  
Csf Biomarkers

scholarly journals Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis

Antioxidants ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1043
Author(s):  
Carmen Peña-Bautista ◽  
Lourdes Álvarez-Sánchez ◽  
Inés Ferrer ◽  
Marina López-Nogueroles ◽  
Antonio José Cañada-Martínez ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Area Under Curve ◽  
Disease Diagnosis ◽  
Csf Biomarkers ◽  
Preclinical Ad ◽  
Aging Populations ◽  
Advanced Stages ◽  
Preclinical Diagnosis ◽  
T Tau ◽  
And Oxidative Stress

Background: Alzheimer disease (AD) is an increasingly common neurodegenerative disease, especially in countries with aging populations. Its diagnosis is complex and is usually carried out in advanced stages of the disease. In addition, lipids and oxidative stress have been related to AD since the earliest stages. A diagnosis in the initial or preclinical stages of the disease could help in a more effective action of the treatments. Methods: Isoprostanoid biomarkers were determined in plasma samples from preclinical AD participants (n = 12) and healthy controls (n = 31) by chromatography and mass spectrometry (UPLC-MS/MS). Participants were accurately classified according to cerebrospinal fluid (CSF) biomarkers and neuropsychological examination. Results: Isoprostanoid levels did not show differences between groups. However, some of them correlated with CSF biomarkers (t-tau, p-tau) and with cognitive decline. In addition, a panel including 10 biomarkers showed an area under curve (AUC) of 0.96 (0.903–1) and a validation AUC of 0.90 in preclinical AD prediction. Conclusions: Plasma isoprostanoids could be useful biomarkers in preclinical diagnosis for AD. However, these results would require a further validation with an external cohort.

[P2-489]: TOWARD AUGMENTING THE UNDERSTANDING OF GENETICS IN MEXICANS AT RISK OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE

2017 ◽  
Vol 13 (7S_Part_17) ◽  
pp. P827-P828
Author(s):  
Angélica Zuno Reyes ◽  
Mellissa Withers ◽  
Esmeralda Matute ◽  
Lourdes Ramírez Dueñas ◽  
Lucy Montoya ◽  
...  
Keyword(s):  
At Risk ◽  
Alzheimer Disease ◽  
Autosomal Dominant

Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease

2021 ◽  
Author(s):  
Virginia D. Buckles ◽  
Chengjie Xiong ◽  
Randall J. Bateman ◽  
Jason Hassenstab ◽  
Ricardo Allegri ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Cognitive Decline ◽  
Autosomal Dominant ◽  
Late Onset

scholarly journals Biological Markers and Alzheimer Disease: A Canadian Perspective

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Hyman M. Schipper
Keyword(s):  
Alzheimer Disease ◽  
Biological Markers ◽  
Primary Care Physicians ◽  
Biomarker Discovery ◽  
Consensus Conference ◽  
Csf Biomarkers ◽  
Protein Levels ◽  
Canadian Perspective ◽  
Diagnostic Confusion ◽  
With Memory

Decreased -amyloid1-42and increased phospho-tau protein levels in the cerebrospinal fluid (CSF) are currently the most accurate chemical neurodiagnostics of sporadic Alzheimer disease (AD). A report (2007) of the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (2006) recommended that biological markers shouldnotbe currently requisitioned by primary care physicians in the routine investigation of subjects with memory complaints. Consideration for such testing should prompt patient referral to a specialist engaged in dementia evaluations or a Memory Clinic. The specialist should consider having CSF biomarkers (-amyloid1-42and phospho-tau) measured at a reputable facility in restricted cases presenting with atypical features and diagnostic confusion, but not as a routine procedure in all individuals with typical sporadic AD phenotypes. We submit that developments in the field of AD biomarker discovery since publication of the 3rd CCCDTD consensus data do not warrant revision of the 2007 recommendations.

Sign in / Sign up

Export Citation Format

Share Document